Epigenetic synergy to increase efficacy of cancer treatmentsEpigenetic synergy to increase efficacy of cancer treatments

Investigating the potential for synergy between the lab's epigenetic drug (a dual histone methyltransferase inhibitor (HKMTi)) and polyADP ribose polymerase inhibitors (PARPi) in high-grade serous ovarian cancer models. Further, exploring whether this HKMTi has the potential to cause immunomodulation which may help stimulate an anti-tumour immune response, possibly in combination with existing immunotherapeutics. For each of these questions, the underlying mechanisms will also be a focus of the investigation, in part via supporting bioinformatics work. The work will begin in human and mouse cell lines, and progress into in vivo murine models.